Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 388Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Breast Neoplasms 115Fallopian Tube Neoplasms 105Colorectal Neoplasms 91Carcinoma, Non-Small-Cell Lung 83Neoplasms 70Pancreatic Neoplasms 63Stomach Neoplasms 57Neoplasm Metastasis 54Prostatic Neoplasms 52Lung Neoplasms 49Melanoma 46Carcinoma, Ovarian Epithelial 44Triple Negative Breast Neoplasms 41Squamous Cell Carcinoma of Head and Neck 37Esophageal Neoplasms 37Carcinoma, Renal Cell 37Colonic Neoplasms 33Urinary Bladder Neoplasms 31Peritoneal Neoplasms 30Uterine Neoplasms 29Head and Neck Neoplasms 29Carcinoma, Hepatocellular 28Vulvar Neoplasms 27Small Cell Lung Carcinoma 25Carcinoma, Transitional Cell 25Uterine Cervical Dysplasia 22Sarcoma 19

Interventions

ipatasertib 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Hysterectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Gynecologic × 90 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT04604613 2026-03-09

Prediction of Recurrence Among Low Risk Endometrial Cancer Patients

M.D. Anderson Cancer Center

Active not recruiting
518 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡